Navigation Links
WorldHeart Reports 2009 Financial Results

SALT LAKE CITY, March 1 /PRNewswire-FirstCall/ -- ("WorldHeart"; Nasdaq: WHRT) - World Heart Corporation, a developer of mechanical circulatory systems, today reported the net loss for the year ended December 31, 2009 of $16.7 million, or a $1.26 loss per basic and diluted share, compared to a $25.3 million net loss, or a $4.37 loss per basic and diluted share in 2008. The decrease was primarily the result of one-time, non-cash clinical and marketing expenses of $6.5 million and one-time debt inducement expense of $3.9 million that we recognized in 2008 related to warrants issued to a strategic partner and the subsequent conversion of debt to common stock.  The decrease in clinical and marketing expenses and the debt inducement expense in 2009 was offset by increases in research and development expenses as well as selling, general and administrative expenses.  These increased costs are associated with the preparation for the Levacor™ VAD Bridge-to-Transplant (BTT) clinical study which received unconditional approval from the U.S. Food and Drug Administration in January 2010.

Revenues were $5,000 for the year ended December 31, 2009, as compared to $1.7 million for the year ended December 31, 2008. The decrease in revenue from 2008 to 2009 is the result of our November 2006 decision to suspend our commercial efforts with respect to the Novacor LVAS and focus our efforts and resources in the development of the Levacor VAD.  In 2007 and 2008, we made the Novacor LVAS available to medical centers only until our inventory was depleted, which occurred in mid-2008. Additionally, we did not have any SPUS (Segmented Poly Urethane Solution) revenue in 2009 as compared to $785,000 in 2008.  The decrease is a result of this revenue being associated with one customer who placed no orders in 2009.  

At December 31, 2009 our balance sheet reflected $6.1 million in cash, cash equivalents and marketable investment securities, which is exclusive of the $7.1 million in net proceeds from the January 2010 private placement. This compares to $20.7 million in cash and cash equivalents at December 31, 2008.

"With our unconditional approval for the BTT clinical study in January coupled with the financing we recently completed, we are well positioned to move our Levacor VAD program forward.  We are excited to offer the world's only fully magnetically levitated, bearingless, implantable centrifugal pump to heart failure patients in the U.S.," added Mr. J. Alex Martin, President and Chief Executive Officer.

About WorldHeart

WorldHeart is a developer of mechanical circulatory support systems headquartered in Salt Lake City, Utah. World Heart's registered office is in Delaware, USA.

Forward-Looking Statements

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the proposed use of proceeds, of the private placement, increase in shareholder value, access to investment capital, and the growth of WorldHeart's overall business,  as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; risks involved in the Levacor VAD Bridge-to-Transplant (BTT) clinical study; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009 and September 30, 2009.

                              WORLD  HEART CORPORATION                        
                       Condensed Consolidated Balance Sheets                  
                              (United States Dollars)                         
                                          December 31, 2009  December 31, 2008
                                          -----------------  -----------------
    Current assets                                                            
      Cash and cash equivalents                  $5,562,670       $20,703,724 
      Marketable investment securities              499,417                 - 
      Trade and other receivables, net               18,907           322,548 
      Inventory, net                                341,614                 - 
      Prepaid expenses and other current                                      
       assets                                       271,966           458,294 
                                                    -------           ------- 
                                                  6,694,574        21,484,566 
    Long-term assets     
      Property and equipment, net                   879,833           651,572 
      Intangible assets, net                              -           107,916 
      Other long-term assets                         36,360           156,360 
                                                     ------           ------- 
                                                    916,193           915,848 
                                                    -------           ------- 
      Total assets                               $7,610,767       $22,400,414 
                                                 ==========       =========== 
    LIABILITIES AND SHAREHOLDERS' EQUITY                                      
    Current liabilities                                                       
      Accounts payable and accrued                                            
       liabilities                               $1,522,199        $1,388,675 
      Accrued compensation                          645,306           897,086 
      Note payable - short term                     102,877                 - 
      Deferred rent                                  18,967             3,671 
                                                     ------             ----- 
                                                  2,289,349         2,289,432 
                                                  ---------         --------- 
    Long-term liabilities                                                      
      Note payable - long term                      580,123                 - 
      Other long term liabilities                    82,309                 - 
                                                     ------               --- 
      Total liabilities                           2,951,781         2,289,432 
                                                  ---------         --------- 
    Commitments and Contingencies                                             
    Shareholders' equity                                                      
      Common stock, no par value,                                             
       13,312,265 shares issued and
       outstanding                              325,279,751       325,087,252 
      Additional paid-in-capital                 18,389,635        17,323,629 
      Cumulative other comprehensive loss        (6,285,577)       (6,285,577)
      Accumulated deficit                      (332,724,823)     (316,014,322)
                                               ------------      ------------ 
      Total shareholders' equity                  4,658,986        20,110,982 
                                                  ---------        ---------- 
      Total liabilities and                                                   
       shareholders' equity                      $7,610,767       $22,400,414 
                                                 ==========       =========== 
                         WORLD HEART CORPORATION                     
             Condensed Consolidated Statements of Operations         
                         (United States Dollars)                     
                                              Year Ended December 31,
                                                 2009          2008 
                                                 ----          ---- 
    Revenue                                     $4,765    $1,732,143 
    Cost of goods sold                        (212,975)     (992,197)
                                              --------      -------- 
    Gross profit (loss)                       (208,210)      739,946 
                                              --------       ------- 
    Operating expenses                                               
      Research and development              10,111,152     9,047,531 
      Selling, general and administrative    5,682,295     4,752,372 
      Clinical and marketing support                 -     6,478,619 
      Restructuring costs                      577,666       131,431 
      Amortization of intangibles              107,916       191,424 
                                               -------       ------- 
        Total operating expenses            16,479,029    20,601,377 
                                            ----------    ---------- 
    Operating loss                         (16,687,239)  (19,861,431)
    Other income (expenses)                    (23,262)   (5,455,353)
                                               -------    ---------- 
    Net loss                              $(16,710,501) $(25,316,784)
                                          ============  ============ 
    Weighted average number of common                                
     shares outstanding: basic and                                   
     diluted                                13,273,462     5,798,940 
                                            ==========     ========= 
    Basic and diluted loss per common                                
     share                                      $(1.26)       $(4.37)
                                                ======        ====== 

SOURCE World Heart Corporation

Back to top



SOURCE World Heart Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NASDAQ Stock Market Confirms WorldHearts Compliance With NASDAQ Listing Rule 5605
2. WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City
3. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
4. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
5. WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
6. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
7. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
8. Questcor Reports Solid Fourth Quarter Results
9. APC Group, Inc. Reports Multi-Year Deal with Medical Device Manufacturer
10. CRF Health Reports Record Growth and Earnings
11. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
Post Your Comments:
(Date:10/8/2015)... and PITTSBURGH , Oct. 8, 2015 ... global pharmaceutical company, will host a conference call and ... pm ET to review the value to be created ... ; TASE) through Mylan,s offer to acquire the company. ... which outlines the compelling proposition for Perrigo shareholders. Mylan,s ...
(Date:10/8/2015)... -- Following months of investigation, Ross Feller Casey , LLP ... the anticoagulant Xarelto,s recommended dosage doesn,t work for as long ... on behalf of a Florida ... didn,t work as the manufacturer suggested. Ross Feller Casey ... behalf of clients from across the country with similar claims. ...
(Date:10/8/2015)... CHARLOTTE, N.C. , Oct. 8, 2015  Clariant, a ... Healthcare Packaging manufacturing facility in Belen, New ... manufactured for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site ... – to meet the ISO 15378:2011 standards, following only ...
Breaking Medicine Technology:
... 2012 announces that a new market ... Vaccines - Top 10 Global ... This market research report package offers an in-depth ... future outlook for vaccines in top 10 global ...
... HAIKOU, China, March 15, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... the "Company"), a fully-integrated specialty pharmaceuticals company in China, today ... Full Year Highlights , ... from $74.4 million in fiscal year 2010. , Income ...
Cached Medicine Technology:
(Date:10/10/2015)... ... 2015 , ... Story Chaser is a one-of-a-kind app that makes ... and inspiring stories and as words drop down and users tap the corresponding word. ... and can be interacted with, making it a more engaging game. Users can use ...
(Date:10/9/2015)... ... ... Doctors on Liens has teamed up with a renowned medical practice, ... to personal injury victims. When personal injury victims suffer major, complex injuries, they ... of conditions ailing them. With the addition of this new group of doctors ...
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is ... – just in time for the cold and flu season, which the Center for ... the U.S., the real start of cold/flu season is the start of the school ...
(Date:10/9/2015)... ... 2015 , ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend ... Ranch in Huntsville, Texas on October 17-21. , "It's very exciting to be ... and executive director, said. “It's a stepping stone into the U.S. elite system where ...
(Date:10/9/2015)... Orleans, LA (PRWEB) , ... October 09, 2015 ... ... with offices serving New Orleans and the surrounding communities, is initiating a combined ... and medical care for unwanted animals in southern Louisiana. , Animal Rescue ...
Breaking Medicine News(10 mins):
... Kensey Nash Corporation (Nasdaq: KNSY ) ... New York Emerging Growth Institutional Investor Forum at The ... 24, 2009.Joseph W. Kaufmann, Kensey Nash,s CEO, will deliver ... The presentation materials will be available on the ...
... PT. RICHMOND, Calif., March 13 Transcept Pharmaceuticals, Inc. ... focused on the development and commercialization of proprietary products ... neuroscience, today announced it will report results for its ... market close. A conference call to review the results ...
... The American Parkinson Disease Association (APDA) and the National ... of Young Onset Parkinson Conferences; First to be held ... 13 The American Parkinson Disease Association,s ... Foundation,s (NPF) Young Onset Parkinson Network announced their first ...
... Finding suggests children with language disorders may benefit from ... Musical training enhances the ability to recognize emotion in ... musical training might benefit people with language problems and ... emotion in sound is a skill that translates across ...
... smartest decision, report says , , FRIDAY, March 13 (HealthDay ... drug plans available through Medicare don,t select the plan ... The report found that the more than 50 standalone ... the best value for their individual medical and financial ...
... Street has earned the number one spot in the ... of Outsourcing Customer Satisfaction Survey, 2008.Andrew DeVoe, CEO and ... recognition from the Health Insurance Industry and all our ... to excellence.""The fact that we have been ranked in ...
Cached Medicine News:
Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
... ACOM.PC turns every standard PC into ... internists, and cardiologists can use their ... access to image data thanks to ... 3 format and the compatible storage ...
... Soarian Cardiovascular Enterprise is a comprehensive ... care continuum from admission to follow-up. ... image acquisition, and diagnostic tools from ... provide a single, longitudinal clinical repository ...
... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
Medicine Products: